ライフサイエンスコーパス: licensure

1 without hemophilia has been increasing since licensure.

2 only to meet the visual acuity criteria for licensure.

3 ntil larger population exposures occur after licensure.

4 ameliorate viremia merits consideration for licensure.

5 d be evaluated in efficacy trials to support licensure.

6 if they possess properties required for drug licensure.

7 for driving outcomes 12 and 48 months after licensure.

8 AIT product to allow an informed decision on licensure.

9 ne design might yield a vaccine suitable for licensure.

10 at informed WHO prequalification and product licensure.

11 accine efficacy and potentially accelerating licensure.

12 didates and potentially useful in support of licensure.

13 ne effectiveness, and regulatory pathways to licensure.

14 , and/or being prescribed ADHD medication at licensure.

15 prescribed medication in the 30 days before licensure.

16 nd to detect potential changes since vaccine licensure.

17 ing exposure during their first 18 months of licensure.

18 for designing phase III trials and ultimate licensure.

19 B vaccines currently under consideration for licensure.

20 and are used to specify criteria for vaccine licensure.

21 , as no current vaccine candidate is nearing licensure.

22 zed to identify changes occurring after MCV4 licensure.

23 ations arise in clinical trials or following licensure.

24 e correlate of protection for recent vaccine licensures.

25 eiving US Food and Drug Administration (FDA) licensure 2005-2012 inclusive in seven neurological diso

26 s of HZ vaccine in healthy adults before its licensure, a series of strategies are proposed for evalu

27 provided efficacy data in support of vaccine licensure.A ZIKV CHIM could be instrumental in determini

28 demonstrating a higher risk of disciplinary licensure actions in physicians who did not maintain boa

29 d adult for a full year; followed by level 2 licensure, allowing unsupervised driving from 5 AM to 9

30 (CNC) rates during their first 18 months of licensure and (2) faster reduction in CNC rates over tim

31 ne receipt during the first RSV season after licensure and 21 or more days before LRTD event.

32 Between licensure and April 1999, the FDA received 15 reports of

33 training, and to examine reasons for delayed licensure and barriers to accessing training.

34 and future educational curricula as well as licensure and certification examinations.

35 field trials in Great Britain to support its licensure and commercialisation.

36 However, the result of more uniform licensure and credentialing may be excessive standardiza

37 However, many challenges to the successful licensure and deployment of an effective tuberculosis va

38 Rates of licensure and driving outcomes among youths who were lic

39 Since the licensure and generalization of an effective measles vir

40 ed States during the 25 years before vaccine licensure and identified 2262 people who died with varic

41 Physicians' state of licensure and medical specialty were identified.

42 This was supported through licensure and orientation to work, career and competence

43 Pre-licensure and post-licensure studies have provided data

44 as significantly advanced our efforts toward licensure and which has the potential to replace the PPD

45 The licensure and WHO prequalification of nOPV2 should be ac

46 The data support the licensure and WHO prequalification of nOPV2.

47 y and immunogenicity data required for nOPV2 licensure and WHO prequalification.

48 of 15.0% had undergone an eye exam prior to licensure, and 3.4% had undergone an eye exam within the

49 view of clinical nurse specialist education, licensure, and certification requirements as well as a d

50 ns concerning advance directives and medical licensure, and literature concerning the fiduciary oblig

51 (26%) disclosed information about clinician licensure, and some used internationally based physician

52 dvance Shigella vaccine development, support licensure, and ultimately facilitate vaccine deployment

53 Using this rule, pathways to licensure are being developed for new vaccines against b

54 t that current vision screening for drivers' licensure, based primarily on visual acuity, may miss im

55 o detect potential risks not observed before licensure because of the relatively small sample size an

56 ng boards, resident education accreditation, licensure boards, and hospital medical staff offices.

57 to the needs of payers and credentialing and licensure bodies and to demonstrate dermatologic value.

58 effects are commonly evaluated pre- and post-licensure, but more complex comparative evaluations have

59 stems to advance investigational products to licensure by conducting trials that de-risk private sect

60 These antitoxins were approved for licensure by the United States Food and Drug Administrat

61 Pre-licensure clinical studies showed that mean serum anti-V

62 (3) participation in the Interstate Medical Licensure Compact (IMLC), permitting psychiatrists to pr

63 cured outside the medical establishment, (2) licensure criteria for prescribers and therapists, (3) c

64 the second vaccine dose per US and European licensure criteria in the per-protocol cohort (n = 389).

65 overall (n=113), European influenza vaccine licensure criteria were fulfilled for responses to A/tur

66 logics Evaluation Research and Review (CBER) licensure criteria were met for all groups.

67 profiles (VE(SYMP) and VE(SUSC)) satisfying licensure criteria.

68 >/=70%, thus fulfilling the US and European licensure criteria.

69 Cross-sectional study using physician licensure data linked with administrative records on all

70 ines were excluded because little or no post-licensure data were available.

71 se trials that establish efficacy and inform licensure decisions or "real world" vaccine usage such a

72 n some regions, so vaccine efficacy and post-licensure effectiveness studies should assess the effect

73 al of Philadelphia network within 2 years of licensure eligibility at age 17 years.

74 At 48 months after licensure eligibility, 75.5% (95% CI, 73.3%-77.7%) and 8

75 Eventual licensure enabling widespread access to phages is the go

76 ory oversight and licensure, policy and post-licensure evaluation, and post-licensure financing-and i

77 re within 6-18 months of passing their state licensure exam at the time of survey administration.

78 could feasibly complete both parts of their licensure examination between May 2007 and March 2011.

79 Adjustment for medical licensure examination scores did not substantially alter

80 potentially adopting a USA based approach to licensure examinations and implementing necessary instit

81 licy and post-licensure evaluation, and post-licensure financing-and identify key stakeholders and sp

82 being considered to facilitate vaccine early licensure, followed by demonstration of efficacy assesse

83 ascertain immunological non-inferiority for licensure for alternate dosing schedules, bridging to ag

84 Efficacy trials that have led to licensure for cervical cancer prevention have used the d

85 nsing (GDL) systems allow full, unrestricted licensure for drivers younger than 18 years only after a

86 Trips at night, precipitation presence, licensure for less than 6 months, and sex were not assoc

87 r providing pivotal data for malaria vaccine licensure for travelers to Africa, and potentially for e

88 s are expected in the near future, including licensure for use in boys and men and the approval of a

89 onjugate vaccine (PCV13) was inferred before licensure from an aggregate correlate of protection esta

90 received emergency use authorization and/or licensure from the US Food and Drug Administration and t

91 nce has declined following varicella vaccine licensure, herpes zoster (HZ) cases may play a larger ro

92 ng, even if it were not required for driving licensure; however, only 62% reported always wearing the

93 The pre-licensure immunogenicity assessments of therapeutic prot

94 Since its licensure in 1995, the extensive use of varicella vaccin

95 ed Oka strain VZV vaccine (OkaVZV) since its licensure in 1995.

96 nce challenges predated varicella vaccine US licensure in 1995.

97 Since licensure in 2006, rotavirus vaccines have been introduc

98 in 2009 and mandated for Puerto Rico medical licensure in 2010.

99 up B meningococcal disease (IMD) since their licensure in 2013 and 2014.

100 umber of AIT products successfully obtaining licensure in the analogous time frame is comparably limi

101 Union (EU) and another is being advanced to licensure in the U.S. and U.K. Despite the clear-cut ben

102 Since licensure in the United States, studies have shown that

103 AGE) during the first 10 years since vaccine licensure, including recent evidence from countries with

104 important policy concerns about professional licensure, including why, under current patient-centered

105 nd regulatory assessment, with a goal toward licensure is critical for these products.

106 tion of the safety profile of vaccines after licensure is crucial to accurately characterise safety b

107 Essential for licensure is that the AIT product investigated remains c

108 petition by promoting the reestablishment of licensure laws in the late 1800s.

109 Licensure laws were almost nonexistent, and any citizen

110 Little is known about how state-level driver licensure laws, such as in-person renewal, vision tests,

111 tering the driver license system, includes 3 licensure levels, each with driving restrictions and req

112 verage and payment policy and concerns about licensure, liability, and other issues.

113 and fines, civil monetary penalties, loss of licensure, loss of staff privileges, and exclusion from

114 Recent advancements have led to the licensure of 3 RSV vaccines for older adults and pregnan

115 After licensure of a conjugate vaccine for invasive pneumococc

116 ntified on infant sera supports the case for licensure of a GBS polysaccharide-protein conjugate vacc

117 ntified on infant sera supports the case for licensure of a GBS polysaccharide-protein conjugate vacc

118 Licensure of a Group B streptococcus (GBS) polysaccharid

119 Licensure of a group B Streptococcus (GBS) polysaccharid

120 To support the licensure of a new and safer vaccine to protect people a

121 sing threat of antimicrobial resistance, and licensure of a new generation of typhoid conjugate vacci

122 ying military personnel with development and licensure of an effective tetravalent dengue vaccine a p

123 Key studies that lead to licensure of antiretroviral medications usually involve

124 Licensure of any medical countermeasure may require demo

125 apeutics are advancing, including the recent licensure of baloxavir; however, many remain to be evalu

126 ays to accelerate the regulatory pathways to licensure of combinations and other concrete, innovative

127 With the licensure of maternal respiratory syncytial virus (RSV)

128 c health responses, including production and licensure of new influenza A (H1N1) 2009 monovalent vacc

129 ata from these assays for the evaluation and licensure of new or adapted COVID-19 vaccines.

130 dictive of protection could facilitate rapid licensure of new vaccines.

131 ese models toward the goal of utility in the licensure of next-generation alphavirus vaccines and the

132 termeasures has provoked the development and licensure of novel COVID-19 vaccines in an unprecedented

133 reports to VAERS in the first 2 years after licensure of PCV described generally minor adverse event

134 gy of PPE by MLST in Utah children after the licensure of PCV-7.

135 mmonly present in the United States prior to licensure of PCV-7.

136 therapeutic ethics; training, education, and licensure of practitioners; equity and access; and appro

137 omote the highly accelerated development and licensure of safe and efficacious COVID-19 vaccines in E

138 ss from clinical development towards product licensure of several programs presents challenges to gen

139 ed pathologic classification system and drug licensure of several targeted therapies over the last de

140 assays have been used in the development and licensure of the ChAdOx1 nCoV-19 (AstraZeneca; Oxford Un

141 At roughly the same time, licensure of the combined measles-mumps-rubella-varicell

142 ecipients has been further improved with the licensure of the efficacious and less toxic letermovir.

143 These results build on the recent licensure of the European gene therapy product Glybera f

144 dengue interventions, particularly with the licensure of the first dengue vaccine and promising deve

145 elop safe and effective vaccines resulted in licensure of the first live oral vaccine, tetravalent, r

146 been slower for humans but 2011 will see the licensure of the first viral-vectored vaccine for humans

147 Trial (publicly funded and initiated before licensure of the HPV vaccines), with the aim of assessin

148 Since licensure of the human papillomavirus (HPV) vaccine in 2

149 After US licensure of the Merck varicella vaccine for immunocompe

150 sible viral targets have been identified and licensure of the most advanced clinical compounds can be

151 ediatric pneumococcal empyema (PPE) prior to licensure of the pneumococcal conjugate vaccine (PCV-7)

152 sed on background rates assessed prior to US licensure of the RV5 (2001-2005).

153 pneumoniae have serotype 3 infections since licensure of the seven-valent pneumococcal conjugate vac

154 icity risk is routinely evaluated during the licensure of therapeutic proteins.

155 The licensure of therapeutic vaccines to reduce zoster indic

156 nes against group B streptococcus (GBS), the licensure of these vaccines may have to rely on studies

157 During the first year after US licensure of TIV-HD, no new serious safety concerns were

158 he sporadic nature of henipavirus outbreaks, licensure of vaccines and therapeutics for human use wil

159 However, while development and licensure of vaccines is a major breakthrough, it repres

160 Before licensure of varicella vaccine in 1995, varicella was a

161 siderations for the clinical development and licensure of Zika vaccine candidates including a discuss

162 serogroup B (4CMenB) vaccine was used before licensure on the basis of special consideration by the F

163 that also comply with state/federal laws for licensure or are certified as an ASC and/or are accredit

164 WHO) prequalified vaccines, registration and licensure pathways, participation in WHO-convened joint

165 ection study data in vaccine development and licensure pathways.

166 velopment to emergency use authorization and licensure, pharmacovigilance of vaccine safety and surve

167 More stringent state licensure policies such as vision tests, road tests, and

168 bjectives-advocacy, regulatory oversight and licensure, policy and post-licensure evaluation, and pos

169 2018 using the terms; pre-registration, pre-licensure, "pre-registration", "pre licensure", trainee,

170 urrent US Food and Drug Administration (FDA) licensure process underestimates the potential benefits

171 uch trials may subtract many months from the licensure process, making efficacious vaccines available

172 The Post-Licensure Rapid Immunization Safety Monitoring (PRISM) s

173 sk of intussusception in large trials before licensure, recent postlicensure data from international

174 poor vision among drivers, and adherence to licensure regulations.

175 versight (10 of 43 [23%]) or training and/or licensure requirements (15 of 43 [35%]).

176 icine components, confusing legal issues and licensure requirements, and poor reimbursement.

177 everal issues such as HIPAA, state and local licensure requirements, credentialing and privileging, s

178 ration process and to harmonize training and licensure requirements.

179 valence of vision disorders and adherence to licensure requirements.

180 onal education in palliative care as part of licensure requirements.

181 liative care training, certification, and/or licensure requirements; (iv) that public and private pay

182 ility to purchase, possess, register, obtain licensure, retain, and/or carry a firearm of any sort.

183 For vaccine licensure, short-term efficacy was inferred from serum b

184 n product availability due to differences in licensure status as well as prohibitively high costs.

185 Pre-licensure and post-licensure studies have provided data supporting vaccine

186 Cohort studies, randomized trials, and post-licensure studies have reported reduced natural and vacc

187 While post-licensure studies have shown substantial declines in rot

188 t data may be used together with prospective licensure studies of BNT162b2 efficacy and safety and co

189 ta-analysis, we included observational, post-licensure studies of rotavirus vaccines, published from

190 e settings as anticipated from pre- and post-licensure studies.

191 younger, and biosimilar vaccines, with post-licensure surveillance confirming effectiveness.

192 Post-licensure surveillance is needed to monitor vaccine perf

193 certainty remains about how the professional licensure system regulates physician-spread misinformati

194 the development of a new vaccine through to licensure takes many years, this leaves Africa vulnerabl

195 used by students in preparation for medical licensure testing.

196 d during clinical trials and continued after licensure to fully evaluate the effect of RSV preventive

197 ll as for college or board certification and licensure to practice medicine.

198 ion, pre-licensure, "pre-registration", "pre licensure", trainee, student, students, nurs*, virtual-r

199 s who got 1 of the 2 HPV vaccines in phase 3 licensure trials, virtually all consented to registry-ba

200 ountermeasures against anthrax in support of licensure under the FDA's "Animal Rule." However, a need

201 ical development and the routine use in post-licensure vaccination campaigns existing regulatory requ

202 The analysis of post-licensure vaccine adverse event report data also provide

203 d structural vaccinology (SV) and (iii) post-licensure vaccine success and adverse event surveillance

204 Licensure was based on immunogenicity data comparing PCV

205 h to U.S. Food and Drug Administration (FDA) licensure was tracked.

206 es and treatments against Nipah virus (NiV), licensure will likely require animal models, most import

207 lity of vaccines progressing from phase 2 to licensure within 10 years was 10.0% (95% CI, 2.6% to 16.

208 ines advancing from launch of phase 2 to FDA licensure within 10 years.

209 m phase 1 to 2, phase 2 to 3, and phase 3 to licensure within the total available follow-up time were

210 Surveillance studies in the post-licensure years have shown an increase in non-vaccine ty